Trevi Therapeutics (TRVI) Total Non-Current Liabilities (2018 - 2022)

Trevi Therapeutics' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $15.6 million for Q4 2022.

• In Q4 2022, Total Non-Current Liabilities fell 26.93% year-over-year to $15.6 million; the TTM figure through Dec 2022 stood at $15.6 million (down 26.93% YoY), while the FY2022 annual figure was $15.6 million, down 26.93% from the prior year.
• Total Non-Current Liabilities for Q4 2022 stood at $15.6 million, down from $18.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $55.7 million in Q3 2020, with the low at $9.4 million in Q4 2018.
• The 4-year median for Total Non-Current Liabilities is $19.8 million (2022), against an average of $21.9 million.
• Peak annual rise in Total Non-Current Liabilities reached 8.31% in 2021, while the deepest fall reached 64.0% in 2021.
• Trevi Therapeutics' Total Non-Current Liabilities stood at $9.4 million in 2018, then surged by 108.41% to $19.7 million in 2020, then gained by 8.31% to $21.3 million in 2021, then decreased by 26.93% to $15.6 million in 2022.
• Business Quant data shows TRVI's Total Non-Current Liabilities at $15.6 million in Q4 2022, $18.4 million in Q3 2022, and $20.9 million in Q2 2022.